Sutro Biopharma Inc. (STRO) Prices 11M Share Common Offering at $7.75/Sh

Sutro Biopharma, Inc. (NASDAQ: STRO) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $7.75 per share. The gross proceeds from this offering are expected to be approximately $85.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. Sutro has also granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock in connection with the public offering. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about May 14, 2020, subject to the satisfaction of customary closing conditions.

Cowen, Piper Sandler and Wells Fargo Securities are acting as joint book-running managers in the offering.

Sutro intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and marketable securities, to fund the continued clinical development of STRO-001 and STRO-002 and the remainder to fund the further development of its technology platform, including manufacturing, to broaden its pipeline of product candidates, and for working capital and general corporate purposes.

You May Also Be Interested In

• Charter Communications closes $4.75 billion senior secured notes offering
• Amylyx Pharmaceuticals launches $350M common stock offering
• Zentalis closes $92.6M public offering of common stock